Figure 1.

Outcomes among patients with relapsed/refractory Hodgkin lymphoma treated with PD‐1 inhibitors. (A): Overall survival of entire cohort from the initiation of PD‐1 inhibitor. (B): Progression‐free survival of entire cohort from the initiation of PD‐1 inhibitor. (C): Progression‐free survival stratified by best overall response to checkpoint inhibitor.

Abbreviations: CR, complete response; PD, progressive disease; PD‐1, programmed cell death protein‐1; PR, partial response; SD, stable disease.